East China Pharmaceutical (000963) announced in the evening of November 26 that the company and its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
(hereinafter referred to as "Zhongmei Huadong") have obtained the production approval documents and new drug certificates for datomomycin and datomomycin for injection
Daptomycin is the first product of cyclolipin antibiotic family
Its chemical structure and mechanism of action are different from all kinds of antibiotics
It is the only new type of antibiotic that has been used in clinic after oxazolidinone antibiotics in the past 40 years
It is mainly used in the treatment of Staphylococcus aureus (including methicillin resistant strains), pyogenic Candida and azoospermia Complex skin and soft tissue infections (csssi) caused by Candida lactis, Neisseria gonorrhoeae, and Enterococcus faecalis (vancomycin sensitive strain), and bacteremia (SAB) caused by Staphylococcus aureus, including right infective endocarditis caused by methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA) （RIE）。
Huadong pharmaceutical said it was the first manufacturer in China to obtain the new drug certificate and production approval of datomomycin.